A randomized controlled trial on raloxifene in breast cancer patients demonstrated significant reductions in new vertebral fractures with a concurrent decrease in the ER+ breast cancer occurrence compared to placebo [63,64]. These results were supported in the multiple outcomes of raloxifene evaluation (MORE_ trial, where raloxifene showed efficacy in treating osteoporosis and hormone-responsive breast cancer without an increased risk of tissue proliferative side effects [64]. The gene discussed is ESR1; the disease is osteoporosis.